Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AGEM-102
- Development stage
- Preclinical
- Lead developer
- AGeM Bio
- Modality
- Gene Therapies, Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intratumoral
01
Overview
AGEM-102 is an engineered mesenchymal stem cell (MSC) therapy developed by AGeM Bio for the treatment of glioblastoma, sarcoma, and other solid tumors. Utilizing the proprietary TrafEn non-viral gene delivery platform, the MSCs are engineered to co-express cytosine deaminase (CDUPRT) and interferon-beta (IFN-β). The mechanism involves the local conversion of the prodrug 5-fluorocytosine (5-FC) into the cytotoxic agent 5-fluorouracil (5-FU) within the tumor microenvironment, coupled with the immunomodulatory effects of IFN-β to enhance anti-tumor activity. The program is currently in the IND-enabling stage of development.
- Other names
- CDUPRT-IFNb-engineered MSCCDUPRT-IFNb_MSCCDUPRT-IFNβ_MSC
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on AGEM-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AGEM-102.